Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: Recommendations from the International Bladder Cancer Group

Journal of Clinical Oncology

Volumn 34, Issue 16, 2016, Pages 1935-1944

  Kamat, Ashish M ^a   Sylvester, Richard J ^b   Böhle, Andreas ^c   Palou, Joan ^d   Lamm, Donald L ^e   Brausi, Maurizio ^f   Soloway, Mark ^g   Persad, Raj ^h   Buckley, Roger ⁱ   Colombel, Marc ^j   Alfred Witjes, J ^k  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b EORTC DATA CENTER   (Belgium)

^c HELIOS AGNES KARLL HOSPITAL   (Germany)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e UNIVERSITY OF ARIZONA   (United States)

^f District of Vignola   (Italy)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h BRISTOL UROLOGICAL INSTITUTE   (United Kingdom)

ⁱ NORTH YORK GENERAL HOSPITAL   (Canada)

^j UNIVERSITÉ LYON 1   (France)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

CANCER IMMUNIZATION; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); CONSENSUS; DISEASE SPECIFIC SURVIVAL; DRUG RESPONSE; DRUG TREATMENT FAILURE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; NON MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVIEW; STUDY DESIGN; SYSTEMATIC REVIEW; BIOASSAY; METHODOLOGY; SAMPLE SIZE; TUMOR RECURRENCE; URINARY BLADDER NEOPLASMS;

BCG VACCINE; CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; HUMANS; NEOPLASM RECURRENCE, LOCAL; RESEARCH DESIGN; SAMPLE SIZE; URINARY BLADDER NEOPLASMS;

EID: 84973091674     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.4070     Document Type: Review

References (57)

1. Jarow JP, Lerner SP, Kluetz PG, et al: Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: Report of a Food and Drug Administration and American Urological Association public workshop. Urology 83:262-264, 2014
2. FDA/AUA Bladder Cancer Workshop: Clinical trial design issues: Development of new therapies for non-muscle invasive bladder cancer. https://www.auanet.org/university/live-course-wip.cfm?id=476id=476&video=202&agenda=2117
3. Amrhein J, Kamat AM, Morales A: Re: Jarrow JP et al: Clinical trial design for the development of new therapies for non-muscle-invasive bladder cancer: Report of a Food and Drug Administration and American Urological Association public workshop (Urology 2014;83:262-265). Urology 84:494-495, 2014
4. van der Meijden AP: The use of the marker tumor concept in Ta, T1 bladder cancer: is it justified? Urol Oncol 7:31-33, 2002
5. McCullough LB: Ethical issues in the use of tumor markers in clinical investigation of the management of bladder cancer. Urol Oncol 7:35-37, 2002
6. Brausi M, Witjes JA, Lamm D, et al: A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 186:2158-2167, 2011
7. Kamat AM, Witjes JA, Brausi M, et al: Defining and treating the spectrum of intermediate risk non-muscle invasive bladder cancer. J Urol 192:305-315, 2014
8. Lamm D, Persad R, Brausi M, et al: Defining progression in nonmuscle invasive bladder cancer: It is time for a new, standard definition. J Urol 191: 20-27, 2014
9. Porten SP, Willis D, Kamat AM: Variant histology: role in management and prognosis of non-muscle invasive bladder cancer. Curr Opin Urol 24: 517-523, 2014
10. Babjuk M, Burger M, Zigeuner R, et al: European Association of Urology: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2013. Eur Urol 64:639-653, 2013
11. American Urological Association: Guideline for the management of nonmuscle invasive bladder cancer (stages Ta,T1, and Tis): 2007 update. http://www.auanet.org/education/guidelines/bladder-cancer.cfm
12. National Comprehensive Cancer Network: Clinical practice guidelines in oncology: Bladder cancer, version 1. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#site
13. Burger M, Grossman HB, Droller M, et al: Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: A meta-analysis of detection and recurrence based on raw data. Eur Urol 64:846-854, 2013
14. Lamm DL, Blumenstein BA, Crissman JD, et al: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study. J Urol 163:1124-1129, 2000
15. Sylvester RJ, Brausi MA, Kirkels WJ, et al: EORTC Genito-Urinary Tract Cancer Group: Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 57:766-773, 2010
16. Oddens J, Brausi M, Sylvester R, et al: Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: One-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 63:462-472, 2013
17. Sylvester RJ, Oosterlinck W, Witjes JA: The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: A systematic review of the published results of randomized clinical trials. Eur Urol 53:709-719, 2008
18. Kamat AM, Vlahou A, Taylor JA, et al: Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer. Urol Oncol 32: 1069-1077, 2014
19. Yates DR, Brausi MA, Catto JW, et al: Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer. Eur Urol 62:1088-1096, 2012
20. Nieder AM, Brausi M, Lamm D, et al: Management of stage T1 tumours of the bladder: International consensus panel. Urology 66:108-125, 2005 (suppl 1)
21. Martin FM, Kamat AM: Definition and management of patients with bladder cancer who fail BCG therapy. Expert Rev Anticancer Ther 9:815-820, 2009
22. O'Donnell MA, Boehle A: Treatment options for BCG failures. World J Urol 24:481-487, 2006
23. Lerner SP, Dinney C, Kamat AM, et al: Short communication: Clarification of bladder cancer disease states following treatment of patients with intravesical BCG. Bladder Cancer 1:29-30, 2015
24. de Reijke TM, Kurth KH, Sylvester RJ, et al: European Organization for the Research and Treatment of Cancer-Genito-Urinary Group: Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: Results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906). J Urol 173:405-409, 2005
25. Sylvester RJ, van der Meijden AP, Witjes JA, et al: High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 66:90-107, 2005 (suppl 1)
26. Herr HW, Milan TN, Dalbagni G: BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: A prospective cohort outcomes study. Urol Oncol 33:108.e1-108.e4, 2015
27. Dalbagni G, Russo P, Sheinfeld J, et al: Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 20:3193-3198, 2002
28. Dalbagni G, Russo P, Bochner B, et al: Phase II trial of intravesicalgGemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 24:2729-2734, 2006
29. Bartoletti R, Cai T, Gacci M, et al: Intravesical gemcitabine therapy for superficial transitional cell carcinoma: Results of a phase II prospective multicenter study. Urology 66:726-731, 2005
30. Mohanty NK, Nayak RL, Vasudeva P, et al: Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience. Urol Oncol 26:616-619, 2008
31. Di Lorenzo G, Perdonà S, Damiano R, et al: Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: A multicenter prospective randomized trial. Cancer 116:1893-1900, 2010
32. Addeo R, Caraglia M, Bellini S, et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: Evaluation of efficacy and tolerance. J Clin Oncol 28: 543-548, 2010
33. McKiernan JM, Masson P, Murphy AM, et al: Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 24:3075-3080, 2006
34. Laudano MA, Barlow LJ, Murphy AM, et al: Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology 75:134-137, 2010
35. Barlow LJ, McKiernan JM, Benson MC: The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: A single institution experience. World J Urol 27:331-335, 2009
36. Bassi PF, Volpe A, D'Agostino D, et al: Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder: Results of a phase I study. J Urol 185: 445-449, 2011
37. McKiernan JM, Barlow LJ, Laudano MA, et al: A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guerin refractory nonmuscle invasive bladder cancer. J Urol 186:448-451, 2011
38. Joudi FN, Smith BJ, O'Donnell MA: Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24:344-348, 2006
39. Witjes J, Hendricksen K, Gofrit O, et al: Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: Experience of the European Synergo working party. World J Urol 27:319-324, 2009
40. Nativ O, Witjes JA, Hendricksen K, et al: Combined thermochemotherapy or recurrent bladder cancer after bacillus Calmetteuerin. J Urol 182:1313-1317, 2009
41. Halachmi S, Moskovitz B, Maffezzini M, et al: Intravesical mitomycin combined with hyperthermia for patients with T1G3 ransitional cell carcinoma of the bladder. Urol Oncol 29:259-264, 2011
42. Waidelich R, Stepp H, Baumgartner R, et al: Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol 165:1904-1907, 2001
43. Berger AP, Steiner H, Stenzl A, et al: Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: A single center study. Urology 61:338-331, 2003
44. Breyer BN, Whitson JM, Carroll PR, et al: Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol Oncol 28:510-514, 2010
45. Denzinger S, Fritsche HM, Otto W, et al: Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: Do risk factors define feasibility of bladder-sparing approach? Eur Urol 53:146-152, 2008
46. Thalmann GN, Markwalder R, Shahin O, et al: Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol 172: 70-75, 2004
47. van den Bosch S, Alfred Witjes J: Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: A systematic review. Eur Urol 60: 493-500, 2011
48. Herr HW, Sogani PC: Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 166:1296-1299, 2001
49. Dalbagni G, Russo P, Bochner B, et al: Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 24:2729-2734, 2006
50. Skinner EC, Goldman B, Sakr WA, et al: SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin. J Urol 190: 1200-1204, 2013
51. Morales A, Herr H, Steinberg G, et al: Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guérin. J Urol 193:1135-1143, 2015
52. Rosevear HM, Lightfoot AJ, Birusingh KK, et al: National BCG/Interferon Investigator Group: Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ. J Urol 186:817-823, 2011
53. Steinberg G, Bahnson R, Brosman S, et al: The Valrubicin Study Group: Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. J Urol 163: 761-767, 2000
54. Gallagher BL, Joudi FN, Maymí JL, et al: Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy. Urology 71:297-301, 2008
55. Böhle A, Jocham D, Bock PR: Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169:90-95, 2003
56. Hinotsu S, Akaza H, Naito S, et al: Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumor for non-muscle-invasive bladder cancer. BJU Int 108:187-195, 2011
57. Malmström PU, Sylvester RJ, Crawford DE, et al: An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 56:247-256, 2009